US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell Endpoints.
Janine Sengstack believes she may have found the next big breakthrough in diabetes and obesity. Her company, Junevity, has searched through hundreds …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Chinese companies dominate global gene therapy competition with 48 programs vs 20 in US, targeting expensive Western treatments…
The FDA's new path, the status of animal testing, and other biotech news from The Readout
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and…
Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan…
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
Prime wins Beam arbitration, clearing path to clinic
